Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inhaled ribavirin (CCI15106) in healthy subjects and COPD patients
NCT03243760Phase 1Terminated
- Sponsor
- GSK
- Start
- Feb 2016
- Primary completion
- Jul 2016
- Modality
- Inhalation Devices, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of CCI15106 in chronic obstructive pulmonary disease (COPD) (11 arms), sponsored by GSK. Primary endpoints: Number of participants with adverse events at 46 days, Number of subjects with abnormal clinical hematology test findings at 46 days and 7 more. Started Feb 2016; status: terminated.
02
Drugs
CCI15106
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT03243760.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03243760.